The FDA originally approved Cyltezo in 2017. Now, pharmacists can substitute it for AbbVie’s Humira without needing a prescriber to change the prescription.
Cyltezo, a tumor necrosis factor blocker, is approved to treat several diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
Cyltezo is the second interchangeable biosimilar product approved by the agency.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.